TI
ALLO icon

Trexquant Investment’s Allogene Therapeutics ALLO Stock Holding History

Trexquant Investment’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,336
Closed -$250K – 1428
2023
Q2 		$250K Sell
50,336
-36,924
-42% -$200K 0.01% 1245
2023
Q1 		$431K Sell
87,260
-24,625
-22% -$158K 0.01% 1058
2022
Q4 		$704K Buy
+111,885
New +$1.04M 0.02% 778
2022
Q3 		– Sell
-14,853
Closed -$169K – 1326
2022
Q2 		$169K Buy
+14,853
New +$132K 0.01% 1388
2021
Q3 		– Sell
-24,321
Closed -$634K – 1101
2021
Q2 		$634K Buy
+24,321
New +$694K 0.05% 416
2020
Q4 		– Sell
-11,207
Closed -$423K – 989
2020
Q3 		$423K Sell
11,207
-4,073
-27% -$154K 0.03% 768
2020
Q2 		$654K Sell
15,280
-12,201
-44% -$441K 0.05% 564
2020
Q1 		$534K Buy
27,481
+13,421
+95% +$320K 0.04% 631
2019
Q4 		$365K Buy
+14,060
New +$387K 0.02% 670

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Trexquant Investment's ALLO Position: Q3 2023 in Review

Trexquant Investment sold out of Allogene Therapeutics (ALLO) in Q3 2023, closing a stake of 50,336 shares — an estimated $250K sold.

Trexquant Investment first reported a position in ALLO in Q4 2019 and held it in 9 quarters. The position peaked at $704K in Q4 2022. 154 funds tracked by Wall St. Rank hold ALLO as of Q3 2023.

  • Trexquant Investment reported no remaining Allogene Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Trexquant Investment sold 50,336 Allogene Therapeutics shares in Q3 2023, an estimated $250K.
  • Trexquant Investment first reported a position in Allogene Therapeutics in Q4 2019 and held it in 9 quarters.
  • Trexquant Investment's Allogene Therapeutics position peaked at $704K in Q4 2022.
  • 154 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2023.

Based on Trexquant Investment's 13F filing for Q3 2023, filed 13 Nov 2023.